This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Print Page   |   Contact Us   |   Sign In   |   Register
Community Search
WCBP 2015: Round Table Notes
Share |

Below you will find links to notes taken during the Round Table session at WCBP 2015.  

If you have questions regarding the links, please contact Project Coordinator Anna Lingel (alingel@casss.org).

 

 

   
Table 1 - Subvisible Particle Methods Click Here 
Table 2 - Clinical Support of CMC Decision  Click Here
Table 3 - In-vitro Replacements for In-vivo Assays and New Technologies for Vaccine Characterization  Click Here
Table 4 - Analytical Methods - Is the Method Design Robust & "Suitable for Intended Purpose?"
             Use of DOE in Method Development
Click Here 
Table 5 - Protein Aggregation Click Here
Table 6 - Bioassays Click Here
Table 7 - Immunogenicity Assays Click Here 
Table 8 - Residual Impurities Other than HCP Click Here
Table 9 -  Method Transfer Click Here
Table 10 - Hot Topics in Pre-approved Inspections Click Here 
Table 11 - Hot Topics in GMP Inspections  Click Here
Table 12 - Due Diligence Assessments Click Here
Table 13 - Outsourcing to CMO's and CTO's Click Here
Table 14 - Extractable / Leachable Risk Assessment  Click Here
Table 15 - Product Specified Monographs  Click Here
Table 16 - Breakthrough Products and Accelerated Development Click Here 
Table 17 - Forced Degradation and Accelerated Stability Studies  Click Here
Table 18 - Global Excipient Testing Requirements Click Here
Table 19 - Analytical Considerations for Comparators Used in Clinical Studies  Click Here
Table 20 - Biosimilars #1 Click Here 
Table 21 - Biosimilars #2 Click Here 
Table 22 - CMC Statistics  Click Here
Table 23 - Drug Product Comparability Assessments  Click Here
Table 24 - Clonality of Cell Lines Click Here
Table 25 - The Future of WCBP Click Here 
Table 26 - Oligonucleotide Therapeutics and mRNA Click Here 
Table 27 - Control Strategies for Personalized Medicines  Click Here
   
   

 





more Calendar

1/28/2019 » 1/31/2019
CMC Strategy Forum and WCBP 2019

1/29/2019 » 1/31/2019
WCBP 2019 Live Stream

3/12/2019 » 3/13/2019
CMC Strategy Forum Latin America 2019

Featured Members
William Weiss, Eli Lilly and CompanyFind out more about Will in this month's Member Spotlight!

Membership Software Powered by YourMembership  ::  Legal